Pear Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Boston--(business wire)--pear therapeutics, inc. (nasdaq: pear), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (pdts), today reported results for its third quarter ended september 30, 2022. “pear is making strong and steady progress toward our mission of making pdts mainstream medicine,” said corey mccann, m.d., ph.d., president and chief executive officer of pear therapeutics. “once again, we delivered significant quarter-over-quarter revenue growth. we continue to break down the barriers to patient access for pdts, evidenced by our increasing payment rate and new coverage decisions. in addition, we’ve taken significant steps to reduce operating expenses in 2023, including the difficult decision to reduce our workforce...

Boston--(business wire)--pear therapeutics, inc. (nasdaq: pear), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (pdts), today reported financial results for its first quarter ended march 31, 2022. “our momentum in 2021 continued into 2022 with strong revenue and prescription volume growth in the first quarter,” said corey mccann, m.d., ph.d., president and chief executive officer of pear therapeutics. “we continue to expand the reach of our products with advances such as the availability of reset® and reset-o® in spanish, expansion into new states like oklahoma and michigan, and recognition from cms via a hcpcs code establishing an important reimbursement milestone for pdts...

Boston--(business wire)--pear therapeutics to present at 2022 rx and illicit drug summit

Boston--(business wire)--pear therapeutics, inc. (nasdaq: pear), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (pdts), today reported financial results for its fourth quarter and full year 2021 ended december 31, 2021. fourth quarter 2021 financial results pear’s total revenue for the fourth quarter of 2021 was $1.3 million, compared with $34 thousand for the fourth quarter of 2020, with the increase over the prior year period primarily related to product sales of its three fda-authorized products. full year 2021 financial and operational performance metrics results in 2021, pear achieved strong financial results and commercial progress from its portfolio of marketed products across key performance metrics of prescriptions, fulfillment, covered lives, and revenue...

Pear Therapeutics (NASDAQ: PEAR ) stock is falling on Friday after the company's recent bankruptcy filing continues to weigh on its shares. Pear Therapeutics announced its bankruptcy filing while markets were closed for Black Friday.

Pear Therapeutics (NASDAQ: PEAR ) stock is climbing higher on Tuesday despite the company's plans to explore strategic alternatives. That news was first announced by the company before markets opened on Friday.

The heavy selling pressure might have exhausted for Pear Therapeutics, Inc. (PEAR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Pear is focusing on its established substance abuse products now, putting development on a hold. Performance has been good into onboarding payors that have good coverage in markets where substance abuse is a problem.

Pear Therapeutics Inc. (NASDAQ:PEAR ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Meara Murphy – Senior Director-Corporate Communications Corey McCann – President and Chief Executive Officer Ronan O'Brien – General Counsel Julia Strandberg – Chief Commercial Officer Yuri Maricich – Chief Medical Officer Chris Guiffre – Chief Financial Officer and Chief Operating Officer Erin Brenner – Chief Product Development Officer Conference Call Participants Eric Percher – Nephron Research Marie Thibault – BTIG Neena Bitritto-Garg – Citi Steve Braun – Cowen Keay Nakae – Chardan Rahul Rakhit – LifeSci Capital Operator Good afternoon, everyone...

Lots of payors are adding reSET to their covered benefit plans, and savings results far exceed prices of the products, usually leaving about 50% in surplus for the health system. Payor contract economics is making timing issues for revenue recognition, but run-rate revenue still indicates Pear is still annualising $12 million in revenue.

Pear Therapeutics, Inc. (NASDAQ:PEAR ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of Corporate Communications Ronan O'Brien - General Counsel and Chief Compliance Officer Corey McCann - President and Chief Executive Officer Chris Guiffre - Chief Financial Officer and Chief Operating Officer Yuri Maricich - Chief Medical Officer Julia Strandberg - Chief Commercial Officer Conference Call Participants Judah Frommer - Credit Suisse Michael Cherny - Bank of America Neena Garg - Citi Eric Percher - Nephron Research Rahul Rakhit - LifeSci Capital Keay Nakae - Chardan Marie Thibault - BTIG Operator Good afternoon, everyone. Welcome to the Pear Therapeutics Second Quarter 2022 Earnings Conference Call.

Pear Therapeutics (PEAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Penny stocks with unusual options activity today. The post Penny Stocks To Buy Now?

Fulfilment rates are growing relative to last quarter, and so are prescriptions. Government traction is becoming more evident as states mandate coverage of Pear products for all resident Medicaid members, and payment rates should rise on account of that.